322 related articles for article (PubMed ID: 23327199)
1. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.
Wu J; Zhou L; Liu J; Ma G; Kou Q; He Z; Chen J; Ou-Yang B; Chen M; Li Y; Wu X; Gu B; Chen L; Zou Z; Qiang X; Chen Y; Lin A; Zhang G; Guan X
Crit Care; 2013 Jan; 17(1):R8. PubMed ID: 23327199
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
Liu F; Wang HM; Wang T; Zhang YM; Zhu X
BMC Infect Dis; 2016 Sep; 16():488. PubMed ID: 27633969
[TBL] [Abstract][Full Text] [Related]
3. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.
Li C; Bo L; Liu Q; Jin F
Int J Infect Dis; 2015 Apr; 33():90-6. PubMed ID: 25532482
[TBL] [Abstract][Full Text] [Related]
4. The Therapeutic Effects of Thymosin α1 Combined with Human Immunoglobulin (Ig) and Bundles on Severe Sepsis: a Retrospective Study.
Li Y; Li CS
Clin Lab; 2015; 61(8):907-16. PubMed ID: 26427133
[TBL] [Abstract][Full Text] [Related]
5. Si-ni-tang (a Chinese herbal formula) for improving immunofunction in sepsis: study protocol for a pilot randomized controlled trial.
Zeng R; Zheng Y; Fan R; Zhou G; Zhang Y; Mai S; Xie D; Weng Y; Du J; Han Y; Lai F
Trials; 2019 Aug; 20(1):537. PubMed ID: 31462310
[TBL] [Abstract][Full Text] [Related]
6. [Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial].
Zhou LX; Tan JJ; Li YN; Luo HT; Shao YH; Qiang XH; Yu TO; Ma MY; Mao KJ; Fang B
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(15):1028-33. PubMed ID: 19595251
[TBL] [Abstract][Full Text] [Related]
7. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients.
Srisawat N; Tungsanga S; Lumlertgul N; Komaenthammasophon C; Peerapornratana S; Thamrongsat N; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S; Tungsanga K; Kellum JA
Crit Care; 2018 Oct; 22(1):279. PubMed ID: 30367647
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.
Chen H; He MY; Li YM
Chin Med J (Engl); 2009 Apr; 122(8):883-8. PubMed ID: 19493408
[TBL] [Abstract][Full Text] [Related]
9. Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients.
Liu D; Yu Z; Yin J; Chen Y; Zhang H; Xin F; Fu H; Wan B
J Crit Care; 2017 Jun; 39():259-266. PubMed ID: 28069319
[TBL] [Abstract][Full Text] [Related]
10. Ulinastatin and/or thymosin α1 for severe sepsis: A systematic review and meta-analysis.
Feng Z; Shi Q; Fan Y; Wang Q; Yin W
J Trauma Acute Care Surg; 2016 Feb; 80(2):335-40. PubMed ID: 26517783
[TBL] [Abstract][Full Text] [Related]
11. Thymosin alpha 1 treatment for patients with sepsis.
Pei F; Guan X; Wu J
Expert Opin Biol Ther; 2018 Jul; 18(sup1):71-76. PubMed ID: 30063866
[TBL] [Abstract][Full Text] [Related]
12. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.
Wang X; Li W; Niu C; Pan L; Li N; Li J
Inflammation; 2011 Jun; 34(3):198-202. PubMed ID: 20549321
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.
Iino S; Toyota J; Kumada H; Kiyosawa K; Kakumu S; Sata M; Suzuki H; Martins EB
J Viral Hepat; 2005 May; 12(3):300-6. PubMed ID: 15850471
[TBL] [Abstract][Full Text] [Related]
14. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
Jia Z; Feng Z; Tian R; Wang Q; Wang L
Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.
Arase Y; Tsubota A; Suzuki Y; Suzuki F; Kobayashi M; Someya T; Akuta N; Hosaka T; Saitoh S; Ikeda K; Kobayashi M; Kumada H
Intern Med; 2003 Oct; 42(10):941-6. PubMed ID: 14606705
[TBL] [Abstract][Full Text] [Related]
16. Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis.
Han D; Shang W; Wang G; Sun L; Zhang Y; Wen H; Xu L
Int Immunopharmacol; 2015 Dec; 29(2):377-382. PubMed ID: 26522590
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
Liu J; Shen Y; Wen Z; Xu Q; Wu Z; Feng H; Li Z; Dong X; Huang S; Guo J; Zhang L; Chen Y; Li W; Zhu W; Du H; Liu Y; Wang T; Chen L; Teboul JL; Annane D; Chen D
Front Immunol; 2021; 12():673693. PubMed ID: 34408744
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis.
Xiang XS; Li N; Zhao YZ; Li QR; Li JS
Inflammation; 2014 Apr; 37(2):402-16. PubMed ID: 24122349
[TBL] [Abstract][Full Text] [Related]
19. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
Mutchnick MG; Lindsay KL; Schiff ER; Cummings GD; Appelman HD; Peleman RR; Silva M; Roach KC; Simmons F; Milstein S; Gordon SC; Ehrinpreis MN
J Viral Hepat; 1999 Sep; 6(5):397-403. PubMed ID: 10607256
[TBL] [Abstract][Full Text] [Related]
20. [Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patients with severe sepsis: a prospective, randomized, controlled clinical trial].
Li YN; Zhou LX; Qiang XH; Yu TO; Mao KJ; Feng B; Wen WB; Zou YC; Li WY; Li C
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Mar; 21(3):139-42. PubMed ID: 19278581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
